[
  {
    "ts": null,
    "headline": "Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases",
    "summary": "Tokyo, Japan and Cambridge and London, UK, 30 September 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that it has reached a second important R&D milestone under its multi-target discovery collaboration with AbbVie focused on neurological diseases, resulting in a payment of US$10 million to Nxera. Nxera and AbbVie entered this multi-target collaboration in 2022 to leverage Nxera’s NxWave™ platform to discover novel medicines targeting G protein-coupled receptors (GP",
    "url": "https://finnhub.io/api/news?id=2298e5f99c5e46e680e7ed2b7a9f84b2532cd2c87c240ff6018933a715e5e467",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759188600,
      "headline": "Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases",
      "id": 136934077,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Tokyo, Japan and Cambridge and London, UK, 30 September 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that it has reached a second important R&D milestone under its multi-target discovery collaboration with AbbVie focused on neurological diseases, resulting in a payment of US$10 million to Nxera. Nxera and AbbVie entered this multi-target collaboration in 2022 to leverage Nxera’s NxWave™ platform to discover novel medicines targeting G protein-coupled receptors (GP",
      "url": "https://finnhub.io/api/news?id=2298e5f99c5e46e680e7ed2b7a9f84b2532cd2c87c240ff6018933a715e5e467"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Seeks FDA Nod for Tavapadon to Treat Parkinson's Disease",
    "summary": "ABBV files for FDA approval of tavapadon, a once-daily oral Parkinson's drug backed by late-stage TEMPO studies.",
    "url": "https://finnhub.io/api/news?id=d85492ed089349e0a05353cdf9d8c7bb58c2135d065b8e2a33dd58d639ab1c52",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759170960,
      "headline": "AbbVie Seeks FDA Nod for Tavapadon to Treat Parkinson's Disease",
      "id": 136934078,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "ABBV files for FDA approval of tavapadon, a once-daily oral Parkinson's drug backed by late-stage TEMPO studies.",
      "url": "https://finnhub.io/api/news?id=d85492ed089349e0a05353cdf9d8c7bb58c2135d065b8e2a33dd58d639ab1c52"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Inc. stock outperforms competitors on strong trading day",
    "summary": "AbbVie Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=1e77d5f4cd03dee511be029902757301a3a2544ecc30549f5d622ccda8d48e18",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759163520,
      "headline": "AbbVie Inc. stock outperforms competitors on strong trading day",
      "id": 136921406,
      "image": "",
      "related": "ABBV",
      "source": "MarketWatch",
      "summary": "AbbVie Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=1e77d5f4cd03dee511be029902757301a3a2544ecc30549f5d622ccda8d48e18"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Breaks Ground on New North Chicago Active Pharmaceutical Ingredient Manufacturing Facility",
    "summary": "AbbVie (NYSE: ABBV) today announced the start of construction of its new active pharmaceutical ingredient (API) manufacturing plant in North Chicago, Illinois. This is a significant milestone in AbbVie's ongoing efforts to expand its U.S. manufacturing network, capabilities and capacity.",
    "url": "https://finnhub.io/api/news?id=11332679af81f46ffb8a7a992aee44b13ec704b8163104fbad7e1f7688a5c58c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759161600,
      "headline": "AbbVie Breaks Ground on New North Chicago Active Pharmaceutical Ingredient Manufacturing Facility",
      "id": 136915709,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (NYSE: ABBV) today announced the start of construction of its new active pharmaceutical ingredient (API) manufacturing plant in North Chicago, Illinois. This is a significant milestone in AbbVie's ongoing efforts to expand its U.S. manufacturing network, capabilities and capacity.",
      "url": "https://finnhub.io/api/news?id=11332679af81f46ffb8a7a992aee44b13ec704b8163104fbad7e1f7688a5c58c"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie to launch ovarian cancer drug in UK at US price",
    "summary": "President Donald Trump has been demanding that drugmakers align domestic prices with the lowest levels paid by comparable high-income countries under the \"most-favored-nation\" policy.  The U.S. pays nearly three times more for prescription drugs compared to other developed nations.  Last week, Bristol Myers Squibb said it planned to launch schizophrenia drug Cobenfy in the UK next year at a price matching its U.S. list price.",
    "url": "https://finnhub.io/api/news?id=ba93347d811077215858a95fc64b884a8d3c6cccd5cb4776865c8f3b1a75b6e9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759151465,
      "headline": "AbbVie to launch ovarian cancer drug in UK at US price",
      "id": 136915710,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "President Donald Trump has been demanding that drugmakers align domestic prices with the lowest levels paid by comparable high-income countries under the \"most-favored-nation\" policy.  The U.S. pays nearly three times more for prescription drugs compared to other developed nations.  Last week, Bristol Myers Squibb said it planned to launch schizophrenia drug Cobenfy in the UK next year at a price matching its U.S. list price.",
      "url": "https://finnhub.io/api/news?id=ba93347d811077215858a95fc64b884a8d3c6cccd5cb4776865c8f3b1a75b6e9"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know",
    "summary": "Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
    "url": "https://finnhub.io/api/news?id=a873e347f11b26b8bd0e69f5e772fb812ff735c9ec109bf04dc9287503ea19e9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759150805,
      "headline": "AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know",
      "id": 136915711,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
      "url": "https://finnhub.io/api/news?id=a873e347f11b26b8bd0e69f5e772fb812ff735c9ec109bf04dc9287503ea19e9"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Announces UK Pricing Strategy for ELAHERE® (mirvetuximab soravtansine-gynx)",
    "summary": "AbbVie (NYSE: ABBV) today announced plans to launch ELAHERE® (mirvetuximab soravtansine-gynx) in the U.K. at a list price equal to the U.S., reflecting the advanced innovation and value of the treatment for adult patients with folate receptor-alpha (FRα) positive, platinum-resistant high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens.1 ELAHERE is the first-and-only approved FRα-directed antibody drug",
    "url": "https://finnhub.io/api/news?id=b3b95a5161dab2f55750fd9fd987ba97089a618e14037b5f64fb65836236a465",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759150800,
      "headline": "AbbVie Announces UK Pricing Strategy for ELAHERE® (mirvetuximab soravtansine-gynx)",
      "id": 136915712,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (NYSE: ABBV) today announced plans to launch ELAHERE® (mirvetuximab soravtansine-gynx) in the U.K. at a list price equal to the U.S., reflecting the advanced innovation and value of the treatment for adult patients with folate receptor-alpha (FRα) positive, platinum-resistant high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens.1 ELAHERE is the first-and-only approved FRα-directed antibody drug",
      "url": "https://finnhub.io/api/news?id=b3b95a5161dab2f55750fd9fd987ba97089a618e14037b5f64fb65836236a465"
    }
  }
]